Trials / Completed
CompletedNCT00127023
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 944 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 11 Months – 21 Months
- Healthy volunteers
- Accepted
Summary
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
Detailed description
Separate injections of the licensed Priorix (MMR vaccine) and Varilrix (chickenpox vaccine) serve as control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Measles, Mumps, Rubella and Chickenpox (live vaccine) |
Timeline
- Start date
- 2005-05-01
- Completion
- 2005-11-01
- First posted
- 2005-08-05
- Last updated
- 2016-09-21
Locations
85 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00127023. Inclusion in this directory is not an endorsement.